Our Pipeline

Accelerating the delivery of medicines to patients with unmet need

[image placeholder – do not delete]

We are a global company working to accelerate the development and commercialization of important new treatment options that have the potential to improve patient care and outcomes. The diverse development candidates in our pipeline have one thing in common – they are being developed to address conditions with significant unmet patient need.  We have a team of patient-focused experts in drug development who recognize the critical importance of accelerating the development of our pipeline in order to bring new medicines to patients more quickly.

We are also leveraging our unparalleled DrugOME technology and Digital Innovation platform to develop potentially first- or –best-in-class therapies across multiple indications and to speed delivery of new medicines to patients who need new treatment options.  

*Sumitovant is the majority-owner of Myovant Sciences, a publicly listed company (NYSE: MYOV)

Myovant aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. The company has two FDA-approved drugs for the treatment of: 1) symptoms of uterine fibroids, and 2) advanced prostate cancer.

Click here to view Myovant’s product pipeline.

Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for a range of urologic conditions. The company has an FDA-approved drug for the treatment of overactive bladder (OAB).

Click here to view Urovant’s product pipeline.

Enzyvant is a commercial-stage biotechnology company with a focus on regenerative medicines for rare diseases. The company has one FDA-approved therapy for the treatment of pediatric congenital athymia.

Click here to view Enzyvant’s product pipeline.

Altavant Sciences is a clinical stage biopharmaceutical company formed to advance promising therapies that treat rare respiratory diseases with an initial therapeutic focus in pulmonary arterial hypertension (PAH).

Click here to view Altavant’s product pipeline.

Spirovant Sciences is a biotechnology company and a leader in the development of gene therapies for cystic fibrosis (CF) and other lung diseases.

Click here to view Spirovant’s product pipeline.